Cagrilintide has no approved label, so every dose figure here traces back to published trials rather than a prescribing guideline. The Phase 2 obesity monotherapy trial tested once-weekly subcutaneous doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg, reached through a dose-escalation period of up to six weeks before a 26-week treatment phase.[1][2][3]
Reviewed for accuracy · Last reviewed July 8, 2026The Phase 2 obesity trial escalated the once-weekly dose over about six weeks before a maintenance period:
In the semaglutide combination (CagriSema), the Phase 3 REDEFINE trials used a 2.4 mg cagrilintide maintenance dose paired with 2.4 mg semaglutide in a single once-weekly injection. The escalation table below mirrors the stepwise trial approach, but because cagrilintide is still investigational, treat these numbers as a description of what was studied, not a recommendation.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.